Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S436-S439. doi: 10.1093/cid/ciaa1521.
This is the first report of ceftazidime-avibactam resistance caused by the blaKPC-33 mutation through the D179Y variant during the treatment of blaKPC-2-positive Klebsiella pneumoniae-related infections in China. The blaKPC-33-containing K. pneumoniae was susceptible to meropenem-vaborbactam, cefepime-zidebactam, tigecycline, and polymyxin B. The blaKPC-33 gene was located on a 77 551-bp transformable plasmid harboring qnrS1 and blaLAP-2. Detecting blaKPC-33-positive K. pneumoniae clinical strains is important for infection control.
这是中国首例 blaKPC-33 突变通过 D179Y 变体导致头孢他啶-阿维巴坦耐药的报告，该突变发生在 blaKPC-2 阳性肺炎克雷伯菌相关感染治疗期间。携带 blaKPC-33 的肺炎克雷伯菌对美罗培南-法硼巴坦、头孢吡肟-他唑巴坦、替加环素和黏菌素 B 敏感。blaKPC-33 基因位于一个可转化的 77551bp 质粒上，该质粒携带 qnrS1 和 blaLAP-2。检测 blaKPC-33 阳性肺炎克雷伯菌临床株对感染控制很重要。
